Interactive

FEATURED VIDEO

Image

FDA Risk vs. Benefit: The Drug Safety Debate After 50 Years

Length: 11:10

Why thalidomide shows that drug safety is not a black-and-white issue. A former FDA official explains why thalidomide was brought back. And patient and consumer groups debate risk tolerance and the need for incentives to create new treatments.

View

More Videos

eLEARNING WHITEPAPER

eLEARNING WHITEPAPER FEATURE

Low-cost, Non-dilutive Financing for Acquiring Commercial Stage Products: A Guide to Revenue Interest Financing

Does an undervalued biopharma company have an alternative to using equity or convertible debt? Are there alternatives to traditional term debt (which might fund only 50-75% of the acquisition price but can encumber all current and future...

View

More Whitepapers